Literature DB >> 6150841

[Autoantibodies against the exocrine pancreas and against intestinal goblet cells in the diagnosis of Crohn's disease and ulcerative colitis].

W Stöcker, M Otte, S Ulrich, D Normann, K Stöcker, G Jantschek.   

Abstract

It was demonstrated by indirect immunofluorescence that Crohn's disease and ulcerative colitis are serologically distinct. In 59 patients with Crohn's disease, confirmed by endoscopy and histology, 23 (39%) had serum autoantibodies against exocrine pancreas; in 17 (29%) the titre was 1 : 100 or higher. In 46 patients with confirmed ulcerative colitis pancreas antibodies were demonstrated only twice, in 100 healthy control subjects only 3 times, with titres less than 1 : 100. Pancreas antibodies do not occur in high concentrations in pancreatitis; titres higher than 1 : 100 therefore suggest Crohn's disease. The pancreas antibodies of patients with Crohn's disease were predominantly immunoglobulins IgA and IgG, twice they were IgD and once IgM, never IgE. In 6 patients the pancreas antibodies fixed complement. Autoantibodies against intestinal goblet cells were found only in patients with ulcerative colitis (13 of 46 = 28%). The titres range was from 1 : 10 to 1 : 1000. The goblet-cell antibodies consisted only of IgA and IgG, never reacting with complement. These results indicate that determining pancreas and goblet-cell antibodies alone will make it possible to diagnose either Crohn's disease or ulcerative colitis in more than a quarter of patients with chronic inflammatory intestinal disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6150841     DOI: 10.1055/s-2008-1069485

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  10 in total

1.  Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease: prevalence, characteristics and diagnostic value.

Authors:  Evgenija Homsak; Dusanka Micetić-Turk; Borut Bozic
Journal:  Wien Klin Wochenschr       Date:  2010-05       Impact factor: 1.704

2.  Pancreatic autoantibodies in Greek patients with inflammatory bowel disease.

Authors:  Ioannis E Koutroubakis; Dimitrios Drygiannakis; Konstantinos Karmiris; Ioannis Drygiannakis; Sokratis Makreas; Elias A Kouroumalis
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

Review 3.  Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.

Authors:  Weiwei Jiang; Xuhang Li
Journal:  Mol Diagn Ther       Date:  2015-06       Impact factor: 4.074

4.  Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking.

Authors:  C Tysk; E Lindberg; G Järnerot; B Flodérus-Myrhed
Journal:  Gut       Date:  1988-07       Impact factor: 23.059

5.  Anti-pancreatic antibody in Turkish patients with inflammatory bowel disease and first-degree relatives.

Authors:  Huseyin Demirsoy; Kamil Ozdil; Ozdal Ersoy; Besir Kesici; Cetin Karaca; Canan Alkim; Nihat Akbayir; Levent Kamil Erdem; Mehmet Derya Onuk; Hulya Tugrul Beyzadeoglu
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

Review 6.  New serological markers in pediatric patients with inflammatory bowel disease.

Authors:  Márta Kovács; Katalin Eszter Müller; Mária Papp; Péter László Lakatos; Mihály Csöndes; Gábor Veres
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

7.  Crohn's disease associated with pancreatitis of unknown etiology: a case report.

Authors:  F Omata; S Arakawa; H Takahashi; F Ueno
Journal:  Gastroenterol Jpn       Date:  1993-06

8.  Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease.

Authors:  Polychronis Pavlidis; Ourania Romanidou; Dirk Roggenbuck; Maria G Mytilinaiou; Faris Al-Sulttan; Christos Liaskos; Daniel S Smyk; Andreas L Koutsoumpas; Eirini I Rigopoulou; Karsten Conrad; Alastair Forbes; Dimitrios P Bogdanos
Journal:  Clin Dev Immunol       Date:  2012-10-17

9.  The Novel Crohn's Disease Marker Anti-GP2 Antibody Is Associated with Ileocolonic Location of Disease.

Authors:  Valentina Somma; Hani Ababneh; Ahmad Ababneh; Simona Gatti; Vittorio Romagnoli; Emanuele Bendia; Karsten Conrad; Dimitrios P Bogdanos; Dirk Roggenbuck; Gino Ciarrocchi
Journal:  Gastroenterol Res Pract       Date:  2013-05-15       Impact factor: 2.260

Review 10.  CUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseases.

Authors:  Christos Liaskos; Eirini I Rigopoulou; Timoklia Orfanidou; Dimitrios P Bogdanos; Christos N Papandreou
Journal:  Clin Dev Immunol       Date:  2013-04-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.